multiple myeloma

39 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

$Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma$

Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma

A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.

Section: Hematology-OncologyJun 2, 2026

Bone Marrow Immune Profiling Identifies a Practical Infection Risk Score in Multiple Myeloma

A large multicenter study links specific bone marrow immune cell patterns to infection risk in multiple myeloma and proposes a clinically relevant immune score that may support minimally invasive monitoring.

multiple myeloma

Latest news

Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma

Bone Marrow Immune Profiling Identifies a Practical Infection Risk Score in Multiple Myeloma

Slow but Steady: t(11;14) Myeloma Shows Superior Outcomes Despite Delayed MRD Negativity with Quadruplet Therapy

When Targeting Becomes a Double-Edged Sword: How Loss of GPRC5D May Fuel Multiple Myeloma Progression

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4

Venetoclax-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: A Critical Appraisal of the Phase III CANOVA Study

Iberdomide-Based Oral Triple Therapy Extends Progression-Free Survival to 17.6 Months in Relapsed Multiple Myeloma: Results from the ICON Study

Comprehensive Summary of Talquetamab Monotherapy and Combination Therapy in Relapsed or Refractory Multiple Myeloma

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data

Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma

Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results

From Discovery to Breakthroughs: How Multiple Myeloma Survival Has Doubled in 20 Years

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma